Cancer Chemotherapy and Pharmacology

, Volume 74, Issue 1, pp 1–13

Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories

  • Lei Cheng
  • Wei Ren
  • Li Xie
  • Ming Li
  • Jiang Liu
  • Jing Hu
  • Bao-Rui Liu
  • Xiao-Ping Qian
Review Article

DOI: 10.1007/s00280-014-2489-6

Cite this article as:
Cheng, L., Ren, W., Xie, L. et al. Cancer Chemother Pharmacol (2014) 74: 1. doi:10.1007/s00280-014-2489-6

Abstract

Anti-epidermal growth-factor receptor (EGFR) monoclonal antibody (MoAb) treatment for chemotherapy refractory or metastatic colorectal cancer has obtained great achievement. However, not every colorectal patient responds to such molecular-targeted agent well. Biomarkers associated with anti-EGFR resistance are not limited to KRAS mutation up to now. It was recently reported that cross-talking molecular effectors interacted with EGFR-related pathway were also negative predictor for anti-EGFR treatment. However, the limited data, controversial results, and contradictories between in vitro and clinical studies restrict the clinical application of these new biomarkers. Although the current theory of tumor microenvironment supported the application of multi-target treatment, the results from the clinical studies were less than expected. Moreover, WHO or RECIST guideline for response assessment in anti-EGFR MoAb treatment was also queried by recent AIO KRK-0306 trial. This review focuses on these controversies, contradictories, and limitations, in order to uncover the unmet needs in current status of anti-EGFR MoAb treatment in colorectal cancer.

Keywords

Colorectal cancerEGFRBRAFRASCetuximabPanitumumab

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Lei Cheng
    • 1
  • Wei Ren
    • 1
  • Li Xie
    • 1
  • Ming Li
    • 2
  • Jiang Liu
    • 1
  • Jing Hu
    • 1
  • Bao-Rui Liu
    • 1
  • Xiao-Ping Qian
    • 1
  1. 1.Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing UniversityClinical Cancer Institute of Nanjing UniversityNanjingChina
  2. 2.Department of Biological Science and Technology and State Key Laboratory of Pharmaceutical Biotechnology, School of Life SciencesNanjing UniversityNanjingChina